Results 81 to 90 of about 9,558 (217)

Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter [PDF]

, 2015
The SLC22A1 influx transporter is expressed on the basolateral membrane of hepatocytes and is involved in the excretion of numerous cations. Inhibition of SLC22A1 by several antiretrovirals, such as the protease inhibitor darunavir, has not previously ...
Liptrott, NJ, Moss, DM, Owen, A, Siccardi, M   +3 more
core   +2 more sources

Highlights from the 24th conference on retroviruses and opportunistic infections, 13-16 February 2017, Seattle, Washington, USA [PDF]

, 2017
From the 13th to 16th February 2017, researchers from around the world convened for the 24th annual Conference on Retroviruses and Opportunistic Infections (CROI) at the Washington State Convention Center in Seattle, Washington.
Bhagani, Sanjay, Colby, Donn J, Crowell, Trevor A, Gathogo, Esther N, Hill, Andrew, Hsu, Denise, Kinloch, Sabine, Lyall, Hermione, Malatinková, Eva, Polyak, Christina, Psomas, Christina, Trypsteen, Wim, Vandekerckhove, Linos   +12 more
core   +5 more sources

Overcoming barriers, driving progress: Clinical science at IAS 2025

Journal of the International AIDS Society, Volume 29, Issue 3, March 2026.
Abstract Introduction The 13th IAS Conference on HIV Science, held in Kigali, Rwanda (13–17 July 2025), highlighted key advances in clinical research. Presentations focused on sustaining HIV treatment and prevention amid financial constraints, innovations in long‐acting oral antiretrovirals, and the management of comorbidities and co‐infections ...
Ezequiel Cordova, Simiso Sokhela, Jasmini Alagaratnam, Juan Ambrosioni   +3 more
wiley   +1 more source

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project

Infection and Drug Resistance, 2018
Paola Bagella,1 Giuseppe VL De Socio,2 Elena Ricci,3 Barbara Menzaghi,4 Canio Martinelli,5 Nicola Squillace,6 Paolo Maggi,7 Giancarlo Orofino,8 Leonardo Calza,9 Laura Carenzi,3 Benedetto Maurizio Celesia,10 Giovanni Penco,11 Antonio Di Biagio,12 Laura ...
Bagella P, De Socio GVL, Ricci E, Menzaghi B, Martinelli C, Squillace N, Maggi P, Orofino G, Calza L, Carenzi L, Celesia BM, Penco G, Di Biagio A, Valsecchi L, Vichi F, Colombo V, Parruti G, Dentone C, Falasca K, Bonfanti P, Madeddu G   +20 more
doaj  

Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals. [PDF]

, 2017
Our study aimed to investigate the short-term effect of combination antiretroviral therapy (cART) on cognitive performance and functional and structural connectivity and their relationship to plasma levels of antiretroviral (ARV) drugs.
Arduino, Roberto C, Luque, Amneris, Ma, Qing, Mapstone, Mark, Miller, Eric, Qiu, Xing, Schifitto, Giovanni, Tivarus, Madalina, Wang, Lu, Weber, Miriam, Zhong, Jianhui, Zhuang, Yuchuan   +11 more
core   +1 more source

Exploring the impact of baseline and on‐treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study

HIV Medicine, Volume 27, Issue 3, Page 386-396, March 2026.
Abstract Objectives The gp120‐directed attachment inhibitor fostemsavir was effective in people with multidrug‐resistant (MDR) HIV‐1 in the BRIGHTE study. Understanding factors associated with virologic response can help clinicians optimize treatment and identify individuals for fostemsavir‐based regimens.
M. Gartland, X. Wang, Q. Liao, B. Li, F. Du, M. Krystal, A. R. Tenorio, A. Pierce, J. R. Castillo‐Mancilla   +8 more
wiley   +1 more source

Safety, Tolerability, and Metabolic Effects of Long-Acting Cabotegravir and Rilpivirine in HIV Care: A Comprehensive Review

Viruses
The use of long-acting cabotegravir and rilpivirine (LA CAB/RPV) is a novel approach to manage human immunodeficiency virus (HIV). This injectable regimen offers benefits such as an improved quality of life, reduced stigma and enhanced treatment ...
Martina Bottanelli, Antonella Castagna, Camilla Muccini   +2 more
doaj   +1 more source

Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study

Viruses, 2015
At Week 96 of the Single-Tablet Regimen (STaR) study, more treatment-naïve subjects that received rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) developed resistance mutations compared to those treated with efavirenz (EFV)/FTC/TDF by population ...
Danielle P. Porter, Martin Daeumer, Alexander Thielen, Silvia Chang, Ross Martin, Cal Cohen, Michael D. Miller, Kirsten L. White   +7 more
doaj   +1 more source

Interventions for neurocognitive dysfunction [PDF]

, 2017
Purpose of review: To evaluate current barriers to HIV cure strategies and interventions for neurocognitive dysfunction with a particular focus on recent advancements over the last three years. Recent findings: Optimal anti-retroviral therapy (ART) poses
Brew, B, Ellero, J, Lubomski, M
core   +2 more sources

Stability indicating RP-UPLC determination of three antiviral agents: emtricitabine, tenofovir, and rilpivirine in combined pharmaceutical dosage form

Future Journal of Pharmaceutical Sciences
Background The concurrent measurement of emtricitabine, tenofovir, and rilpivirine was achieved using UPLC, employing Analytical Quality by Design (AQbD) principles, which encompass response surface methodology (RSM) and Box–Behnken design (BBD).
Vinutha Kommineni, Spoorthi Pohar, N. Sri Lakshmi, N. Swarna Latha   +3 more
doaj   +1 more source